EGFR and non-small cell lung carcinoma: Numerous important target molecules of AFs in NSCLC and other cancers, such as vascular endothelial growth factor (VEGF) (Zhang 2015) and epidermal growth factor receptor (EGFR) (Oxnard et al., 2011), have all become clinical targets for antitumor angiogenesis.